ABEONA THERAPEUTICS INC

View in Terminal

Loading quotes...

Forecast

The analysts' average price target is €15.98 (+699.00%). The median is €15.38 (+669.00%).

Buy	6
Hold	3
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2000, ABEONA THERAPEUTICS INC has already paid €3,875.87 in dividends. The last payout was in March 2000.

Financials

In the last quarter, ABEONA THERAPEUTICS INC had revenue of €11.91m and net profit of -€4.24m

(EUR)	September 2026	YoY
Revenue	11.91m	-
Gross profit	6.87m	1,751.31%
Net profit	-4.24m	3.48%
EBITDA	-2.96m	81.30%

Fundamentals

Metric	Value
Market capitalization	€126.97m
Number of shares	57.18m
52-week high/low	€6.92 - €2.08
Dividends	No
Beta	1.30
P/E ratio	-2.19
PEG ratio	0.01
P/B ratio	1.13
P/S ratio	3.60

Company profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.